Company Overview and News

10
Fairfax Announces Quarterly Dividend on Series C, D, E, F, G, H, I, J, K and M Preferred Shares and Quarterly Dividend Rate for Series D, F, H and J Shares

2018-06-01 globenewswire
TORONTO, June 01, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX:FFH) (TSX:FFH.U) announces that it has declared the following quarterly dividends per share on its preferred shares:
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

9
Fairfax Completes €150 Million Re-opening of 2.75% Senior Notes Due 2028

2018-05-18 globenewswire
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX:FFH) (TSX:FFH.U) has completed its previously announced offering of an additional €150 million of its 2.75% Senior Notes due 2028 (the “Notes”). Together with the previously issued €600 million aggregate principal amount of notes of this series (the “Original Notes”), there is €750 million aggregate principal amount of notes of this series outstanding.
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

9
First Quarter Financial Results

2018-05-03 globenewswire
(Note: All dollar amounts in this news release are expressed in U.S. dollars except as otherwise noted. The financial results are prepared using the recognition and measurement requirements of International Financial Reporting Standards except as otherwise noted, and are unaudited.)
FXFLF 500413 FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF THOMASCOOK

9
Result of Voting for Directors at Annual and Special Shareholders’ Meeting

2018-04-27 globenewswire
TORONTO, April 27, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX:FFH) (TSX:FFH.U) is pleased to announce the results of the vote on Directors at its April 26, 2018 Annual and Special Shareholders’ Meeting.
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

9
First Quarter Accounting Gain

2018-04-24 globenewswire
TORONTO, April 24, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX:FFH) (TSX:FFH.U) announces that its 67.6% - owned subsidiary, Thomas Cook (India) Limited (“TCIL”), has changed the accounting for its ownership interest in Quess Corp. Limited (“Quess”) from a subsidiary to an associate for its year ended March 31, 2018. As a result of this accounting change, TCIL will de-consolidate Quess and TCIL’s remaining ownership interest in Quess will be recorded at fair value and presented as an investment in an associate company.
FXFLF 500413 FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF THOMASCOOK

9
Fairfax Announces Conference Call

2018-04-19 globenewswire
TORONTO, April 19, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (TSX:FFH) (TSX:FFH.U) will hold a conference call at 8:30 a.m. Eastern Time on Friday, May 4, 2018 to discuss its 2018 first quarter results which will be announced after the close of markets on Thursday, May 3 and will be available at that time on its website www.fairfax.ca. The call, consisting of a presentation by the company followed by a question period, may be accessed at (800) 857-9641 (Canada and U.
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

9
Fairfax Completes US$600 Million Senior Notes Offering

2018-04-17 globenewswire
TORONTO, April 17, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX:FFH) (TSX:FFH.U) has completed its previously announced offering of US$600 million in aggregate principal amount of 4.850% Senior Notes due 2028 (the “Notes”). In anticipation of the offering of the Notes, Fairfax initiated a hedge of the treasury benchmark related to the Notes. After giving effect to the benefit of this hedge, the effective interest rate on the Notes is 4.
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

9
Fairfax Announces Pricing of Senior Notes Offering

2018-04-13 globenewswire
TORONTO, April 12, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX:FFH) (TSX:FFH.U) announces that it has priced its previously announced private offering of US$600,000,000 of Fairfax’s Senior Notes due 2028 (the “Notes”) at an issue price of 99.765%. The Notes will be unsecured obligations of Fairfax and will pay a fixed rate of interest of 4.850% per annum. In anticipation of the offering of the Notes, Fairfax initiated a hedge of the treasury benchmark related to the Notes.
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

9
Fairfax Announces Early Redemption of Notes due June 22, 2020

2018-03-29 globenewswire
TORONTO, March 29, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX:FFH) (TSX:FFH.U) announces that, on April 30, 2018, it is redeeming all of its outstanding 7.25% Senior Notes due June 22, 2020 (the “Notes”) at a redemption price of 109.101% of the principal amount of the Notes plus accrued and unpaid interest, if any. There is approximately C$267.3 million principal amount of Notes currently outstanding.
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

9
Fairfax Announces Pricing of Offering of Senior Notes

2018-03-22 globenewswire
TORONTO, March 22, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX:FFH) (TSX:FFH.U) announces that it has priced a private offering of €600 million of Fairfax’s Senior Notes due 2028 (the “Notes”) at an issue price of 98.791%. The Notes will be unsecured obligations of Fairfax and will pay a fixed rate of interest of 2.750% per annum.
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to TSX:FFH / Fairfax Financial Holdin on message board site Silicon Investor.

Fairfax Financial (FFH.to)